Chiara Lazzari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chiara Lazzari has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Bulotta
Department of Oncology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
1 shared publication - Aurora Mirabile
Department of Otorhinolaryngology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
1 shared publication - Francesca Rita Ogliari
Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy
1 shared publication - Italo DellOca
Department of Radiotherapy, IRCSS San Raffaele Hospital, via Olgettina 60, 20132 Milano, Italy
1 shared publication - Maria Grazia Viganò
Department of Oncology, IRCCS San Raffaele, 20132 Milan, Italy
1 shared publication - Mariacarmela Santarpia
Medical Oncology Unit, Department of Human Pathology “G. Barresi”, University of Messina, 98125 Messina, Italy
1 shared publication
Latest Publications
- Open Access
History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature
Several trials have tried for decades to improve the outcome of extensive disease small cell lung cancer (ED-SCLC) through attempts to modify the standard treatments. Nevertheless, platinum/etoposide combination and topotecan have remained respectively the first and the second line standard treatments for the last 40 years. With the advent of immunotherapy, this scenario has finally changed. Our review aims to provide an overview of the primary studies on the actual therapeutic strategies available for ED-SCLC patients, and to highlight emerging evidence supporting the use of immunotherapy in SCLC patients.
Open AccessHistory of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature
Several trials have tried for decades to improve the outcome of extensive disease small cell lung cancer (ED-SCLC) through attempts to modify the standard treatments. Nevertheless, platinum/etoposide combination and topotecan have remained respectively the first and the second line standard treatments for the last 40 years. With the advent of immunotherapy, this scenario has finally changed. Our review aims to provide an overview of the primary studies on the actual therapeutic strategies available for ED-SCLC patients, and to highlight emerging evidence supporting the use of immunotherapy in SCLC patients.